Figure 6

The FISH results after EZH2 or TET2 down-regulation or decitabine treatment. (A) There were 5 abnormally marked positions in U937 cells as follows: +8 (2.7%), 20q12 (2.1%), D13S319 (1.1%), RB1 (1.1%), and 1q21 (0.67%). (B) EZH2-siRNA-transfected U937 cells had 7 abnormally marked positions: 7q (8.9%), D13S319 (5.2%), +8 (3.3%), 1q21 (3.1%), 5q− (2.3%), 20q12− (1.8%), and IgH (8.9%). (C) After decitabine treatment of EZH2-siRNA-transfected U937 cells, the number of abnormally marked positions decreased: 1q21 (5.6%), and +8 (9.7%). (D) TET2-siRNA-transfected U937 cells had 7 abnormally marked positions: +8 (10.8%), IgH (10.6%), 1q21 (10.4%), D13S319 (5%), RB1 (4.9%), and 20q12 (3.1%). (E) After decitabine treatment, the number of abnormally marked positions in TET2-siRNA-transfected U937 cells decreased: 1q21 (10.3%), RB1 (9.1%), +8 (8.9%), D13S319 (7.6%), 7q (3.1%), and 20q12 (2.7%). (F) The typical representative pictures of FISH.